Alle Fälle anzeigen
UPC APP 24524/2025
—·EP2493466: NOVEL ANTITUMORAL USE OF CABAZITAXEL
- Verfahrensdetails
- Status—VerfahrensartVerfahrensantragKategorieVerfahrensführungsanordnungen
- Parteien
- Kläger
- Sanofi SA
- Sanofi Winthrop Industrie
- Sanofi-Aventis GmbH
- Sanofi Belgium
- Sanofi-Aventis Deutschland GmbH
- Sanofi S.r.l.
- Sanofi B.V.
- Sanofi - Produtos Farmaceuticos Lda
- Sanofi AB
- Sanofi A/S
Vertreter: Frédéric Chevallier (McDermott Will & Schulte)BeklagteVertreter: Anja Lunze (Taylor Wessing); Elisabeth Greiner (df-mp) - Division
- Munich LD
- Richter
- Matthias Zigann · Presiding Judge and Judge-Rapporteur
- Alima Zana · Legally Qualified Judge
- Tobias Pichlmaier · Legally Qualified Judge
- Carola Wagner · Technically Qualified Judge
- Technology
- Pharmaceutical & Medical
- Sprache
- —
- Erste Entscheidung
- 27. Juni 2025
Entscheidungen
- 2025-06-27Application Rop 333
Procedural order from the Munich Local Division (UPC_CFI_148/2024 and UPC_CFI_503/2024) on Zentiva's application under R. 333 RoP for panel review of the judge-rapporteur's case management order of 8 May 2025 in Sanofi's infringement action concerning EP 2 493 466. The full panel reviewed how preliminary objections should be handled and the timetable for subsequent proceedings.
Rechtsfragen:Panel review of judge-rapporteur order (R. 333 RoP)Preliminary objectionsCase management
Dokumente
- A018985EE4166E1B463B5DBA248BD157_en.pdf2025-06-27EN